NasdaqCM - Nasdaq Real Time Price USD

Filana Therapeutics, Inc. (FLNA)

0.5607 -0.0003 (-0.05%)

As of 1:05:28 PM EST. Market Open.

Chart Range Bar

Loading chart for FLNA

4m ago Powered by Yahoo Scout

Filana’s latest update reported preclinical simufilam findings supporting mitochondrial effects in TSC2-deficient cells. The FDA’s September removal of the clinical hold also cleared the path toward a Phase 2a epilepsy study, with screening expected in Q1 2027. The company remains pre-revenue and relies on clinical validation, cash management, and settlement obligations.

Previous Close 0.5610
Open 0.5723
Bid 1.1300 x 1000
Ask 1.0700 x 1000
Day's Range 0.5600 - 0.5789
52 Week Range 0.5600 - 3.4500
Volume 165,473
Avg. Volume 2,021,387
Market Cap (intraday) 27.086M
Beta (5Y Monthly) -0.45
PE Ratio (TTM) --
EPS (TTM) -0.8700
Earnings Date (est.) Nov 5, 2026
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date Dec 13, 2012
1y Target Est 6.50

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

www.filanatx.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FLNA

71.68%

S&P 500 (^GSPC)

10.80%

1-Year Return

FLNA

82.42%

S&P 500 (^GSPC)

10.70%

3-Year Return

FLNA

97.53%

S&P 500 (^GSPC)

74.03%

5-Year Return

FLNA

99.01%

S&P 500 (^GSPC)

62.75%

Earnings Per Share (GAAP)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -8.6M

Profit Margin 0.00%

FY25

FY26

-12M

-10M

-8M

-6M

-4M

-2M

0.0%

Analyst Price Targets

5.00

6.50 Average

0.5607 Current

8.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/6/2025

Analyst LUCID CAPITAL MARKETS

Rating Action Initiated

Rating Buy

Price Action Announces

Price Target 8

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-7.14%
Return on Equity (ttm)

-55.79%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-42.28M
Diluted EPS (ttm)

-0.8700

Balance Sheet and Cash Flow

Total Cash (mrq)

82.68M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

3.98M

OCGN Ocugen, Inc.

0.7426 +2.47%

AVXL Anavex Life Sciences Corp.

1.2200 +7.02%

VXRT Vaxart, Inc.

0.3910 -4.05%

BNGO Bionano Genomics, Inc.

1.2000 +3.45%

NVAX Novavax, Inc.

9.72 +1.94%

U.S. markets close in 2h 54m

Filana Therapeutics, Inc. (FLNA)

-13.74%

-39.71%

-62.87%

-71.68%

-82.42%

-99.01%

-99.45%

What's happening with FLNA?

Filana Therapeutics, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (GAAP)

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch